Trials / Completed
CompletedNCT02460276
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Lund University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this trial, patients with mantle cell lymphoma will be included, treatment with lenalidomide, rituximab and ibrutinib will be administered in an induction phase for up to 12 cycles, cycle length 28 days. Patients with complete remission, partial response or stable disease will enter a maintenance phase with treatment with ibrutinib and rituximab until progression of disease. The primary objective is to evaluate overall response rate, based on PET and CT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenalidomide | |
| DRUG | Ibrutinib | |
| DRUG | Rituximab |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2015-06-02
- Last updated
- 2020-04-24
Locations
5 sites across 4 countries: Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.gov record NCT02460276. Inclusion in this directory is not an endorsement.